Precision Cancer Immunotherapy
Adularia’s technology is rooted in the discovery of a potent immune mechanism, which is based on insights from the symbiotic interplay between gut microbes and the immune system. Recognizing bacterial metabolites activate a potent anti-tumor immune reaction, the team identified a therapeutic target for immuno-oncology. By focusing on the development of a synthetic small molecule that replicates the mechanism of action of this naturally occurring mechanism, they aim to develop novel immunotherapy.
The therapy target is predominantly expressed in tumor-residing macrophages. Once stimulated, the macrophages release cytokines that activate cytotoxic T-cells, leading to enhanced tumor infiltration and a potent anti-tumor effect. By acting locally in the tumor microenvironment, the team aims to reduce side effects, expand the therapeutic window, and increase the target population that can benefit from immunotherapies.
